BTIG Research Cuts MDxHealth (NASDAQ:MDXH) Price Target to $2.00

MDxHealth (NASDAQ:MDXH) had its price target trimmed by BTIG Research from $4.00 to $2.00 in a research note issued to investors on Friday morning, Marketbeat.com reports. They currently have a buy rating on the stock.

MDXH has been the subject of several other reports. Wall Street Zen upgraded MDxHealth to a “sell” rating in a research report on Saturday, August 15th. TD Cowen reaffirmed a “buy” rating and issued a $1.50 price target (down from $7.00) on shares of MDxHealth in a research note on Thursday, May 14th. William Blair downgraded shares of MDxHealth from an “outperform” rating to a “market perform” rating in a research report on Thursday, May 14th. Finally, Lake Street Capital set a $3.00 price objective on shares of MDxHealth and gave the stock a “buy” rating in a research note on Friday, August 14th. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $2.17.

MDxHealth Price Performance

MDXH stock opened at $0.74 on Friday. MDxHealth has a twelve month low of $0.40 and a twelve month high of $5.33. The company has a market cap of $36.78 million, a P/E ratio of -1.03 and a beta of 1.42. The business’s fifty day moving average is $0.50 and its 200-day moving average is $1.67.

MDxHealth (NASDAQ:MDXH) last announced its quarterly earnings data on Friday, August 14th. The company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.01. The company had revenue of $27.21 million for the quarter, compared to analyst estimates of $26.14 million. Research analysts anticipate that MDxHealth will post -0.49 earnings per share for the current fiscal year.

Institutional Investors Weigh In On MDxHealth

Several large investors have recently made changes to their positions in the stock. Kennedy Capital Management LLC acquired a new stake in shares of MDxHealth in the 3rd quarter valued at about $1,826,000. Marshall Wace LLP bought a new stake in shares of MDxHealth in the fourth quarter valued at about $609,000. Panoramic Capital LLC acquired a new position in shares of MDxHealth during the third quarter worth about $721,000. 683 Capital Management LLC acquired a new position in shares of MDxHealth during the fourth quarter worth about $384,000. Finally, Mink Brook Asset Management LLC grew its holdings in shares of MDxHealth by 64.9% during the fourth quarter. Mink Brook Asset Management LLC now owns 263,420 shares of the company’s stock worth $940,000 after buying an additional 103,686 shares in the last quarter.

About MDxHealth

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.